pomalidomide has been researched along with Pancreatic Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Hanafi, M; Neamati, N | 1 |
| Alvarez, S; Ezell, EL; King, HM; Kizhake, S; Kubica, SP; Law, HC; Mallareddy, JR; Naldrett, MJ; Natarajan, A; Rana, S; Woods, NT; Zahid, M | 1 |
| Dalgleish, AG; Kasow, S; Samad, M; Smith, PL; Yogaratnam, Y | 1 |
| Bastea, LI; Copland, JA; Doeppler, H; Edenfield, B; Fleming, AK; Li, Z; Liou, GY; Pandey, V; Qiu, Y; Storz, P; Tun, HW; von Roemeling, CA | 1 |
| Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, SF; Messersmith, WA; Spigel, DR; Weekes, CD; Yardley, DA | 1 |
1 trial(s) available for pomalidomide and Pancreatic Neoplasms
| Article | Year |
|---|---|
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Thalidomide; Treatment Outcome | 2011 |
4 other study(ies) available for pomalidomide and Pancreatic Neoplasms
| Article | Year |
|---|---|
Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.
Topics: Benzofurans; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mutant Chimeric Proteins; NAD(P)H Dehydrogenase (Quinone); Naphthoquinones; Pancreatic Neoplasms; Proteolysis; Signal Transduction; STAT3 Transcription Factor; Structure-Activity Relationship; Ubiquitin-Protein Ligases | 2021 |
Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Cyclin-Dependent Kinase 9; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteolysis; Pyrazoles; Structure-Activity Relationship; Sulfonamides | 2021 |
Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Deoxycytidine; Drug Interactions; Gemcitabine; Histocompatibility Antigens Class I; Humans; Immunomodulation; Interferon-gamma; Lymphocyte Activation; Oxaliplatin; Pancreatic Neoplasms; Thalidomide; Zoledronic Acid | 2021 |
Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions.
Topics: Animals; Humans; Immunologic Factors; Interferon Regulatory Factors; Macrophages; Mice; Pancreatic Neoplasms; Precancerous Conditions; Thalidomide; Tumor Microenvironment; U937 Cells | 2019 |